Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued on Tuesday, July 11th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will earn ($7.08) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $114.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($8.35) per share.
Other research analysts have also recently issued reports about the stock. Evercore ISI raised shares of Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $60.00 to $80.00 in a research note on Tuesday, June 6th. StockNews.com initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Thursday, May 18th. They issued a “hold” rating on the stock. Finally, Citigroup raised their price objective on shares of Ultragenyx Pharmaceutical from $130.00 to $133.00 in a research note on Wednesday, June 7th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $88.33.
Ultragenyx Pharmaceutical Stock Up 0.7 %
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($2.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.97) by ($0.36). Ultragenyx Pharmaceutical had a negative net margin of 187.31% and a negative return on equity of 149.75%. The business had revenue of $100.50 million during the quarter, compared to analyst estimates of $103.90 million. During the same quarter in the prior year, the company posted ($2.19) earnings per share. The company’s revenue was up 25.8% on a year-over-year basis.
Insider Activity at Ultragenyx Pharmaceutical
In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 4,378 shares of the firm’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $45.00, for a total value of $197,010.00. Following the sale, the executive vice president now directly owns 51,982 shares of the company’s stock, valued at $2,339,190. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 4,378 shares of the stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $45.00, for a total transaction of $197,010.00. Following the sale, the executive vice president now owns 51,982 shares in the company, valued at approximately $2,339,190. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Corazon (Corsee) D. Sanders sold 1,485 shares of the stock in a transaction on Thursday, June 8th. The stock was sold at an average price of $51.65, for a total value of $76,700.25. Following the completion of the transaction, the director now directly owns 9,570 shares in the company, valued at $494,290.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,765 shares of company stock worth $416,366. Company insiders own 6.80% of the company’s stock.
Institutional Trading of Ultragenyx Pharmaceutical
A number of large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its position in Ultragenyx Pharmaceutical by 33.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 951 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 239 shares in the last quarter. Quadrant Capital Group LLC grew its stake in Ultragenyx Pharmaceutical by 111.4% during the fourth quarter. Quadrant Capital Group LLC now owns 924 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 487 shares in the last quarter. Lazard Asset Management LLC raised its holdings in Ultragenyx Pharmaceutical by 36.6% in the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 240 shares during the last quarter. Signaturefd LLC grew its position in shares of Ultragenyx Pharmaceutical by 143.7% during the 4th quarter. Signaturefd LLC now owns 1,462 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 862 shares during the period. Finally, Harbor Capital Advisors Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 26.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 2,264 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 469 shares during the period. 96.56% of the stock is currently owned by institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Read More
- Five stocks we like better than Ultragenyx Pharmaceutical
- Contrarian Play: Beyond Meat Is At An Inflection Point
- Alibaba Just Flashed Green, Very Green
- This Small Cap Stock Surged Over 100%
- The CPI Data Isn’t As Good As You Think It Is
- How to Invest in Gold and Silver
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
